Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 988 across all filing types
Latest filing 2026-03-19 Major Shareholding Noti…
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Change in substantial holding 5 pages 254.2KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Notice of change of interests of substantial shareholder' and references 'Form 604 Corporations Act Section 671B', which is a regulatory form used in Australia to notify changes in substantial shareholdings. The content details changes in voting power and relevant interests of a substantial shareholder, Citigroup Global Markets Australia Pty Limited, including dates and share quantities. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of shareholding changes, fitting the definition of a Major Shareholding Notification.
2026-03-19 English
3 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)
Director's Dealing
2026-03-19 English
3 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)
Director's Dealing
2026-03-19 English
3 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)
Director's Dealing
2026-03-19 English
Notification of cessation of securities - TLX 4 pages 15.2KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of certain securities (Share Appreciation Rights) for Telix Pharmaceuticals Limited. It includes specific information about the securities that have ceased, reasons for cessation, and updated issued capital figures. The document is a formal announcement to the ASX about changes in the company's securities, specifically the cessation of certain equity securities. This type of document is a regulatory announcement related to changes in securities but does not constitute a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive details about the cessation event itself. The document fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-03-17 English
Appendix 3Y Change in Director Interests - C Behrenbruch 3 pages 439.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings and interests of a company director, including shareholdings, options, and performance rights. The document is a formal notification of insider share transactions by a director, including dates, quantities, and nature of changes. There is no financial performance data, earnings information, or management discussion. The content matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length (8479 characters) and detailed transaction data support this classification.
2026-03-17 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.